TY  - JOUR
PY  - 2019//
TI  - Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
JO  - Respiratory medicine case reports
A1  - Tello, K.
A1  - Hoffmann, A.
A1  - Beutel, B.
A1  - Greulich, T.
A1  - Vogelmeier, C.F.
A1  - Richter, M.J.
A1  - Kuhnert, S.
A1  - Böselt, T.
A1  - Alter, P.
A1  - Holland, A.
A1  - Idzko, M.
A1  - Buhl, R.
A1  - Koczulla, A.R.
SP  - 
EP  - 
VL  - 28
IS  - 
N2  - We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma. © 2019 The Authors<p /> <p>Language: en</p>
LA  - en
SN  - 2213-0071
UR  - http://dx.doi.org/10.1016/j.rmcr.2019.100927
ID  - ref1
ER  -